celecoxib has been researched along with Breast Cancer in 141 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer." | 9.41 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. ( Bartlett, J; Bliss, JM; Borley, A; Coleman, R; Coombes, RC; Denkert, C; Dibble, T; Evans, A; Grieve, R; Hicks, J; Kilburn, L; Kunze, CA; Loibl, S; Lu, XL; Makris, A; Mansi, J; Mehta, K; Mousa, K; Murray, E; Palmieri, C; Rautenberg, B; Rhein, U; Schmidt, M; Tovey, H; von Minckwitz, G, 2021) |
| "The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation- induced skin toxicity in patients with breast cancer." | 9.27 | Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer. ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate." | 9.24 | Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. ( Asselain, B; Berger, F; Bertheau, P; Brain, E; Delaloge, S; Espié, M; Giacchetti, S; Guinebretière, JM; Hamy, AS; Lerebours, F; Marty, M; Mathieu, MC; Mazouni, C; Pierga, JY; Reyal, F; Saghatchian, M; Sigal-Zafrani, B; Tembo, O, 2017) |
| "Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP)." | 9.22 | Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. ( Alasino, CM; Mainetti, LE; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2016) |
| "Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients." | 9.20 | Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. ( Akhondzadeh, S; Arya, P; Emami, SA; Esfandbod, M; Kashani, L; Kaviani, A; Mohammadinejad, P; Najafi, M; Zeinoddini, A, 2015) |
| " Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth." | 9.17 | Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. ( Alasino, CM; Mainetti, LE; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2013) |
| "In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15)." | 9.17 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. ( Ayoubi, T; Blok, MJ; Brandão, RD; de Vries, B; Hupperets, PS; Keymeulen, K; Lindsey, P; Smeets, HJ; Tjan-Heijnen, VC; Van de Vijver, KK; van Elssen, CH; Veeck, J, 2013) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 9.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 9.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| " We initiated a randomised controlled pre-surgical study of celecoxib versus no treatment in women with primary breast cancer to determine the effects of COX-2 inhibition on markers of biological response." | 9.14 | Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. ( A'Hern, R; Betambeau, N; Davies, GL; Dowsett, M; Hills, MJ; Martin, LA; Salter, J; Walsh, G; Weigel, MT, 2010) |
| "NAF and plasma samples were collected in women at increased breast cancer risk before and 2 weeks after taking celecoxib 200 or 400 mg twice daily (bid)." | 9.13 | uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer. ( Chen, YC; Flynn, JT; Hewett, JE; Kliethermes, B; Mannello, F; Qin, W; Rottinghaus, G; Sauter, ER; Zhu, W, 2008) |
| "This was a feasibility study of the combination of Exemestane and the cyclooxygenase-2 (COX-2) inhibitor Celecoxib in advanced breast cancer." | 9.12 | A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. ( Canney, PA; Curto, J; Machin, MA, 2006) |
| " To explore the possibility that COX-2 is a therapeutic target, we conducted a phase II study of celecoxib, a selective COX-2 inhibitor, and trastuzumab in patients with HER-2/neu-overexpressing metastatic breast cancer that had progressed while receiving trastuzumab." | 9.11 | Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. ( D'Andrea, GM; Dang, CT; Dannenberg, AJ; Dickler, MN; Hudis, CA; Moasser, MM; Norton, L; Panageas, KS; Seidman, AD; Subbaramaiah, K; Theodoulou, M, 2004) |
| "An outstanding therapeutic potential of luteolin in the treatment of breast cancer has been recorded not just as a chemopreventive and chemotherapeutic agent yet complemented by its synergistic effects with other anticancer therapies such as cyclophosphamide, doxorubicin, and NSAID such as celecoxib, and possible underlying mechanisms." | 9.01 | Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. ( Ahmed, S; Fathi, N; Fratantonio, D; Hasan, MM; Khan, H; Rastrelli, L; Sharifi, S; Ullah, H, 2019) |
| "Our results have demonstrated that celecoxib, a potent and selective COX-2 inhibitor, resulted in significant antiproliferative activity against all examined breast cancer cell lines with IC50 values of 95." | 8.12 | Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models. ( Akileh, BM; AlHiary, AK; Bardaweel, SK; Dahabiyeh, LA; Dennis, JW; Pawling, J; Rahman, AMA; Shalabi, DD, 2022) |
| " Besides, the use of celecoxib is also related to lowering the risk of breast cancer." | 8.02 | Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer. ( Alqahtani, AM; Chandrasekaran, B; Chidambaram, K; Dhanaraj, P; Pino-Figueroa, A; Venkatesan, K, 2021) |
| "This study aimed to develop, evaluate, and optimize the mPEG-PLA/vitamin E-TPGS mixed micelle drug delivery system to encapsulate celecoxib (CXB) and honokiol (HNK) for intravenous treatment of breast cancer." | 7.96 | Tuning mPEG-PLA/vitamin E-TPGS-based mixed micelles for combined celecoxib/honokiol therapy for breast cancer. ( He, K; Jiang, M; Li, J; Liu, Q; Qiu, T; Sun, J; Yang, M; Zhan, S; Zhang, X, 2020) |
| "Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors." | 7.91 | Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. ( Aouchiche, B; Asselain, B; Benchimol, G; Brain, E; Edelman, M; Espié, M; Gao, J; Giacchetti, S; Hamy, AS; Laas, E; Laé, M; Marty, M; Pierga, JY; Pistilli, B; Reyal, F; Tury, S; Wang, X, 2019) |
| " Solid lipid nanoparticles (CLX-SLN), nanostructured lipid carriers (CLX-NLC) and a nanoemulsion (CLX-NE) of celecoxib (CLX), a selective cyclooxygenase-2 inhibitor, were formulated for use in remedy of breast cancer and acute promyelocytic leukemia." | 7.91 | Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. ( Ergüven, M; Üner, M; Yener, G, 2019) |
| " Here, we studied the effect of Celecoxib, a COX-2 inhibitor on two molecular breast cancer subtypes-MDA-MB-231 and SK-BR-3." | 7.85 | Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway. ( Huang, S; Li, J; Wang, G; Zhang, L; Zhao, X, 2017) |
| "To investigate the preventive effect of celecoxib, a specific cyclooxygenase-2 (Cox-2) inhibitor, on the development of chemoresistance in breast cancer cell line, MCF-7, and explore the mechanism of the action." | 7.77 | Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. ( Chen, C; Chen, QY; Shen, HL; Xu, WL; Yang, J, 2011) |
| "The use of celecoxib is associated with a significant decrease in breast cancer risk." | 7.77 | Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. ( Fang, XM; Han, M; Li, BH; Liu, B; Shi, CJ; Wang, JJ; Wen, JK; Zhang, DQ; Zhang, YP, 2011) |
| "To investigate the reversal effect of Celecoxib and Taxol on multidrug resistance (MDR) human breast cancer cells (MCF-7/Taxol) and its underlying mechanism." | 7.77 | [Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism]. ( Chen, YJ; Liu, Q; Liu, XJ; Wang, J, 2011) |
| "We selected celecoxib-resistant (CER) variants from two metastatic cell lines, SUM149 inflammatory breast cancer (IBC) cell line and MDA-MB-231-BSC60 cell line, by culturing them in the presence of celecoxib." | 7.76 | Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. ( Irving, LR; Lucci, A; Singh, B; Tai, K, 2010) |
| " Celecoxib (CX) and minocycline hydrochloride (MH) have both been widely used in treating breast cancer; however, their combined effects on the osseous metastasis of breast cancer have not yet been studied." | 7.74 | The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| " In the present study we evaluated the mechanisms by which a highly selective COX-2 inhibitor, celecoxib, affects tumor growth of two differentially invasive human breast cancer cell lines." | 7.73 | Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. ( Basu, GD; Gendler, SJ; Mukherjee, P; Pathangey, LB; Tinder, TL, 2005) |
| " We found celecoxib (25 microM) significantly reduced uPA protein and mRNA in MDA-MB-231 breast cancer cells following 72 h of treatment." | 7.73 | Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells. ( Andrews, HN; Dunn, SE; Habibi, G; Kucab, JE, 2005) |
| "Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, blocks growth and promotes apoptosis in breast cancer cells." | 7.73 | Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. ( Chada, S; Hunt, KK; Liu, Y; Lucci, A; McKenzie, T; Suh, YJ; Swisher, SG, 2005) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 7.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice." | 7.72 | Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. ( Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L; Zhang, S, 2004) |
| "A total of 64 invasive breast cancer patients were recruited in the N001 Phase II, multicenter, open-label, single-arm study to receive four cycles of FEC (500, 100, 500 mg/m(2)) followed by four cycles of T (100 mg/m(2)) with concurrent CXB (200 mg b." | 6.78 | Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. ( Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY, 2013) |
| "Triple negative breast cancers experience the highest pCR rate of 30%." | 6.75 | A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. ( Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M, 2010) |
| "AI is effective in treating breast cancer and may be safely used preoperatively." | 6.73 | Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. ( Chow, LW; Lam, CK; Loo, WT; Toi, M; Yip, AY, 2008) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment." | 6.71 | Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. ( Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L, 2004) |
| "Despite advances in breast cancer treatment, mortality from breast cancer is still high." | 6.52 | Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review. ( Ch Yiannakopoulou, E, 2015) |
| "Although triple-negative breast cancer accounts for less than one-fifth of breast cancers, it has a higher rate of metastasis and mortality." | 5.91 | Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells. ( Hedayat, M; Jafari, R; Khezri, MR; Majidi Zolbanin, N; Malekinejad, H, 2023) |
| "Celecoxib analogue 4f is a promising multi-targeted lead for the design and synthesis of potent anticancer agents." | 5.72 | Design and Synthesis of Novel Celecoxib Analogues with Potential Cytotoxic and Pro-apoptotic Activity against Breast Cancer Cell Line MCF-7. ( Abdelhaleem, EF; El-Nassan, HB; Kassab, AE; Khalil, OM, 2022) |
| "In spite of the high incidence of breast cancer worldwide, there are few strategies for its chemoprevention, and they have limited adherence mainly due to their serious adverse effects." | 5.51 | Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer. ( de Brito, M; Lopes, LB; Mojeiko, G; Salata, GC, 2019) |
| "Interestingly, human breast cancer tissue samples displayed high expression of OPG, PGE2 and fatty acid synthase (FASN)." | 5.43 | Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis. ( Goswami, S; Sharma-Walia, N, 2016) |
| "To evaluate the role of celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)-negative primary breast cancer." | 5.41 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. ( Bartlett, J; Bliss, JM; Borley, A; Coleman, R; Coombes, RC; Denkert, C; Dibble, T; Evans, A; Grieve, R; Hicks, J; Kilburn, L; Kunze, CA; Loibl, S; Lu, XL; Makris, A; Mansi, J; Mehta, K; Mousa, K; Murray, E; Palmieri, C; Rautenberg, B; Rhein, U; Schmidt, M; Tovey, H; von Minckwitz, G, 2021) |
| "Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies." | 5.40 | Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. ( Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J, 2014) |
| "This study showed that in NMU-induced mammary cancer in rats, the combination of resveratrol and celecoxib led to a significant reduction in all tumor parameters." | 5.40 | Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. ( Bojková, B; Ekmekcioglu, C; Fedoročko, P; Jäger, W; Jendželovský, R; Kajo, K; Kassayová, M; Kisková, T; Kokošová, N; Kubatka, P; Maier-Salamon, A; Mikeš, J; Orendáš, P; Papčová, Z; Rentsen, E; Svoboda, M; Thalhammer, T, 2014) |
| "Celecoxib can inhibit cell proliferation, regulate cell cycle and induce apoptosis, but the underlying mechanisms are still unclear." | 5.35 | [Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway]. ( Li, J; Liu, LH; Sang, MX; Shan, BE; Wang, L; Zhang, C, 2009) |
| "Celecoxib was administered i." | 5.31 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. ( Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001) |
| "The prognostic and predictive role of cyclo-oxygenase-2 (COX2) in breast cancer is still debated, and in particular, its role as a target of COX2 inhibitor (celecoxib) in neoadjuvant setting." | 5.27 | ( Asselain, B; Bertheau, P; Bièche, I; Brain, E; DE Cremoux, P; Giacchetti, S; Guinebretière, JM; Hamy, AS; Lehmann-Che, J; Marty, M; Mathieu, MC; Pierga, JY; Scott, V; Sigal, B; Spyratos, F, 2018) |
| "Celecoxib and low-dose aspirin might decrease risk of breast cancer recurrence." | 5.27 | Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27. ( Badovinac-Crnjevic, T; Budd, GT; Chapman, JW; Clemons, MJ; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Han, L; Higgins, MJ; Ingle, JN; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Strasser-Weippl, K, 2018) |
| "The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation- induced skin toxicity in patients with breast cancer." | 5.27 | Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer. ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate." | 5.24 | Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. ( Asselain, B; Berger, F; Bertheau, P; Brain, E; Delaloge, S; Espié, M; Giacchetti, S; Guinebretière, JM; Hamy, AS; Lerebours, F; Marty, M; Mathieu, MC; Mazouni, C; Pierga, JY; Reyal, F; Saghatchian, M; Sigal-Zafrani, B; Tembo, O, 2017) |
| "Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP)." | 5.22 | Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. ( Alasino, CM; Mainetti, LE; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2016) |
| "The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib." | 5.22 | Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy. ( Alasino, CM; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2016) |
| "Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients." | 5.20 | Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. ( Akhondzadeh, S; Arya, P; Emami, SA; Esfandbod, M; Kashani, L; Kaviani, A; Mohammadinejad, P; Najafi, M; Zeinoddini, A, 2015) |
| " Our preclinical results suggested that combined MCT with cyclophosphamide and celecoxib could inhibit breast cancer growth." | 5.17 | Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. ( Alasino, CM; Mainetti, LE; Perroud, HA; Pezzotto, SM; Queralt, F; Rico, MJ; Rozados, VR; Scharovsky, OG, 2013) |
| "In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15)." | 5.17 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. ( Ayoubi, T; Blok, MJ; Brandão, RD; de Vries, B; Hupperets, PS; Keymeulen, K; Lindsey, P; Smeets, HJ; Tjan-Heijnen, VC; Van de Vijver, KK; van Elssen, CH; Veeck, J, 2013) |
| "Postmenopausal women with estrogen receptor (ER) and/or progesterone (PR) positive stages II-III breast cancers received 8 weeks of exemestane 25 mg daily, followed by 8 weeks of exemestane 25 mg daily and celecoxib 400 mg twice daily." | 5.15 | Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. ( Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM, 2011) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 5.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| " We initiated a randomised controlled pre-surgical study of celecoxib versus no treatment in women with primary breast cancer to determine the effects of COX-2 inhibition on markers of biological response." | 5.14 | Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. ( A'Hern, R; Betambeau, N; Davies, GL; Dowsett, M; Hills, MJ; Martin, LA; Salter, J; Walsh, G; Weigel, MT, 2010) |
| "NAF and plasma samples were collected in women at increased breast cancer risk before and 2 weeks after taking celecoxib 200 or 400 mg twice daily (bid)." | 5.13 | uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer. ( Chen, YC; Flynn, JT; Hewett, JE; Kliethermes, B; Mannello, F; Qin, W; Rottinghaus, G; Sauter, ER; Zhu, W, 2008) |
| "Epidemiologic studies suggest that long term low dose celecoxib use significantly lowers breast cancer risk." | 5.13 | Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. ( Chen, YC; Flynn, JT; Hewett, JE; Qin, W; Rottinghaus, G; Ruhlen, RL; Sauter, ER, 2008) |
| "This was a feasibility study of the combination of Exemestane and the cyclooxygenase-2 (COX-2) inhibitor Celecoxib in advanced breast cancer." | 5.12 | A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. ( Canney, PA; Curto, J; Machin, MA, 2006) |
| " To explore the possibility that COX-2 is a therapeutic target, we conducted a phase II study of celecoxib, a selective COX-2 inhibitor, and trastuzumab in patients with HER-2/neu-overexpressing metastatic breast cancer that had progressed while receiving trastuzumab." | 5.11 | Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. ( D'Andrea, GM; Dang, CT; Dannenberg, AJ; Dickler, MN; Hudis, CA; Moasser, MM; Norton, L; Panageas, KS; Seidman, AD; Subbaramaiah, K; Theodoulou, M, 2004) |
| "An outstanding therapeutic potential of luteolin in the treatment of breast cancer has been recorded not just as a chemopreventive and chemotherapeutic agent yet complemented by its synergistic effects with other anticancer therapies such as cyclophosphamide, doxorubicin, and NSAID such as celecoxib, and possible underlying mechanisms." | 5.01 | Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. ( Ahmed, S; Fathi, N; Fratantonio, D; Hasan, MM; Khan, H; Rastrelli, L; Sharifi, S; Ullah, H, 2019) |
| "Our results have demonstrated that celecoxib, a potent and selective COX-2 inhibitor, resulted in significant antiproliferative activity against all examined breast cancer cell lines with IC50 values of 95." | 4.12 | Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models. ( Akileh, BM; AlHiary, AK; Bardaweel, SK; Dahabiyeh, LA; Dennis, JW; Pawling, J; Rahman, AMA; Shalabi, DD, 2022) |
| " Besides, the use of celecoxib is also related to lowering the risk of breast cancer." | 4.02 | Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer. ( Alqahtani, AM; Chandrasekaran, B; Chidambaram, K; Dhanaraj, P; Pino-Figueroa, A; Venkatesan, K, 2021) |
| "This study aimed to develop, evaluate, and optimize the mPEG-PLA/vitamin E-TPGS mixed micelle drug delivery system to encapsulate celecoxib (CXB) and honokiol (HNK) for intravenous treatment of breast cancer." | 3.96 | Tuning mPEG-PLA/vitamin E-TPGS-based mixed micelles for combined celecoxib/honokiol therapy for breast cancer. ( He, K; Jiang, M; Li, J; Liu, Q; Qiu, T; Sun, J; Yang, M; Zhan, S; Zhang, X, 2020) |
| "Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors." | 3.91 | Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. ( Aouchiche, B; Asselain, B; Benchimol, G; Brain, E; Edelman, M; Espié, M; Gao, J; Giacchetti, S; Hamy, AS; Laas, E; Laé, M; Marty, M; Pierga, JY; Pistilli, B; Reyal, F; Tury, S; Wang, X, 2019) |
| " Solid lipid nanoparticles (CLX-SLN), nanostructured lipid carriers (CLX-NLC) and a nanoemulsion (CLX-NE) of celecoxib (CLX), a selective cyclooxygenase-2 inhibitor, were formulated for use in remedy of breast cancer and acute promyelocytic leukemia." | 3.91 | Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. ( Ergüven, M; Üner, M; Yener, G, 2019) |
| "In MDA-MB-231 and MCF-7 breast cancer cell lines, we investigated the influence of calcitriol and the COX2 inhibitor celecoxib on cell growth via the MTT test, as well as on the protein and mRNA expression of COX2 using western blot and quantitative real-time polymerase chain reaction (qRT-PCR)." | 3.88 | Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines. ( Fischer, D; Friedrich, M; Hoellen, F; Köster, F; Polack, S; Reichert, K; Rody, A; Thill, M; Woeste, A, 2018) |
| " Here, we studied the effect of Celecoxib, a COX-2 inhibitor on two molecular breast cancer subtypes-MDA-MB-231 and SK-BR-3." | 3.85 | Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway. ( Huang, S; Li, J; Wang, G; Zhang, L; Zhao, X, 2017) |
| "Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis." | 3.80 | Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice. ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| "In order to prove whether downregulation of COX-2 (Cyclooxygenase-2) could modulate the epithelial- mesenchymal transition (EMT) of breast cancer, celecoxib and siRNA were respectively used to inhibit COX-2 function and expression in MDA-MB-231 cells." | 3.80 | Silencing of COX-2 by RNAi modulates epithelial-mesenchymal transition in breast cancer cells partially dependent on the PGE2 cascade. ( Cao, J; Li, WT; Lv, SJ; Yang, X; Zhao, CL, 2014) |
| "Tamoxifen (TAM) is widely used in the chemotherapy of breast cancer and as a preventive agent against recurrence after surgery." | 3.79 | Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. ( Das, S; Dey, KK; Kumar, BN; Mandal, M; Mazumdar, A; Parekh, A; Rajput, S, 2013) |
| " We therefore combined chloroquine (CQ), a pharmacological inhibitor of autophagy, with other drugs known to act as ERS aggravators (ERSA), namely nelfinavir (an HIV protease inhibitor) and celecoxib (a cyclooxygenase-2 inhibitor) or its non-coxib analog 2,5-dimethyl-celecoxib (DMC), and investigated combination drug effects in a variety of breast cancer cell lines." | 3.78 | Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. ( Agarwal, P; Chen, TC; Cho, H; Gaffney, KJ; Golden, EB; Hofman, FM; Louie, SG; Petasis, NA; Schönthal, AH; Sharma, N; Thomas, S, 2012) |
| "To investigate the preventive effect of celecoxib, a specific cyclooxygenase-2 (Cox-2) inhibitor, on the development of chemoresistance in breast cancer cell line, MCF-7, and explore the mechanism of the action." | 3.77 | Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. ( Chen, C; Chen, QY; Shen, HL; Xu, WL; Yang, J, 2011) |
| "We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk." | 3.77 | Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. ( Ashok, V; Dash, C; Rohan, TE; Sprafka, JM; Terry, PD, 2011) |
| "The use of celecoxib is associated with a significant decrease in breast cancer risk." | 3.77 | Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. ( Fang, XM; Han, M; Li, BH; Liu, B; Shi, CJ; Wang, JJ; Wen, JK; Zhang, DQ; Zhang, YP, 2011) |
| "To investigate the reversal effect of Celecoxib and Taxol on multidrug resistance (MDR) human breast cancer cells (MCF-7/Taxol) and its underlying mechanism." | 3.77 | [Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism]. ( Chen, YJ; Liu, Q; Liu, XJ; Wang, J, 2011) |
| "We selected celecoxib-resistant (CER) variants from two metastatic cell lines, SUM149 inflammatory breast cancer (IBC) cell line and MDA-MB-231-BSC60 cell line, by culturing them in the presence of celecoxib." | 3.76 | Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. ( Irving, LR; Lucci, A; Singh, B; Tai, K, 2010) |
| " Our study was concerned with evaluating the effects of the selective COX2 inhibitor, celecoxib, on mammary tumorigenesis and aging in HER2/neu transgenic mice (24)." | 3.75 | [The effects of Celebrex on mammary tumorigenesis and aging in HER2/neu transgenic mice]. ( Anisimov, VN; Imianitov, EI; Piskunova, TS; Semenchenko, AV; Sokolenko, AP; Suspitsin, EN; Zabezhinskiĭ, MA, 2009) |
| "116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron." | 3.74 | [Multimodal treatment of pain and nausea in breast cancer surgery]. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2008) |
| " Celecoxib (CX) and minocycline hydrochloride (MH) have both been widely used in treating breast cancer; however, their combined effects on the osseous metastasis of breast cancer have not yet been studied." | 3.74 | The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice. ( Cai, L; Liao, Z; Niu, G; Sun, L; Wei, R, 2008) |
| " A human breast cancer cell line, MDA-MB-231, was implanted in 30 female homozygotous athymic rats that were alternately assigned to either a drug treatment group that received celecoxib on a daily basis for 7 days or a control group that received saline." | 3.74 | MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. ( Brasch, RC; Floyd, E; Fournier, LS; Fu, Y; Lucidi, V; Miller, T; Novikov, V; Shames, DM, 2007) |
| "We first established the cytotoxicity of celecoxib in two COX-2-overexpressing E1A-transfected breast cancer cell lines (MDA-MB-231 and MDA-MB-435) and in two low-COX-2-expressing E1A-transfected cell lines (MCF-7 (breast cancer) and SKOV3." | 3.74 | Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. ( Bartholomeusz, C; Sugimoto, T; Tari, AM; Ueno, NT, 2007) |
| " In the present study we evaluated the mechanisms by which a highly selective COX-2 inhibitor, celecoxib, affects tumor growth of two differentially invasive human breast cancer cell lines." | 3.73 | Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. ( Basu, GD; Gendler, SJ; Mukherjee, P; Pathangey, LB; Tinder, TL, 2005) |
| "We determined that Celecoxib analogues are potent inhibitors of P-Akt signalling and kill breast cancer cells that overexpress HER-2." | 3.73 | Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. ( Cheang, M; Chen, CS; Dunn, SE; Emerman, J; Gilks, CB; Huntsman, D; Kucab, JE; Lee, C; Pollak, M; Yorida, E; Zhu, J, 2005) |
| " We found celecoxib (25 microM) significantly reduced uPA protein and mRNA in MDA-MB-231 breast cancer cells following 72 h of treatment." | 3.73 | Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells. ( Andrews, HN; Dunn, SE; Habibi, G; Kucab, JE, 2005) |
| "Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, blocks growth and promotes apoptosis in breast cancer cells." | 3.73 | Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. ( Chada, S; Hunt, KK; Liu, Y; Lucci, A; McKenzie, T; Suh, YJ; Swisher, SG, 2005) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 3.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "To determine whether COX-2 regulates vascular channel formation, we assessed whether treatment with celecoxib (a selective COX-2 inhibitor) or silencing COX-2 synthesis by siRNA inhibits vascular channel formation by breast cancer cell lines." | 3.73 | A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. ( Basu, GD; Conley, CR; Liang, WS; Mukherjee, P; Pockaj, BA; Stephan, DA; Wegener, LT, 2006) |
| "Alpha-TEA, a nonhydrolyzable ether analog of vitamin E (RRR-alpha-tocopherol), and celecoxib, a specific COX-2 inhibitor, were delivered separately or in combination to investigate their anticancer properties, using MDA-MB-435-FL-GFP human breast cancer xenografts in nude mice." | 3.72 | Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. ( Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L; Zhang, S, 2004) |
| "To assess hyperalgesia in persistent pain patients we performed an additional analysis on patients reporting VAS>30 at 12 months." | 2.82 | Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition. ( Filippini-de Moor, GP; Steegers, MA; van Helmond, N; Vissers, KC; Wilder-Smith, OH, 2016) |
| "A total of 64 invasive breast cancer patients were recruited in the N001 Phase II, multicenter, open-label, single-arm study to receive four cycles of FEC (500, 100, 500 mg/m(2)) followed by four cycles of T (100 mg/m(2)) with concurrent CXB (200 mg b." | 2.78 | Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. ( Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY, 2013) |
| "However, not all breast cancer patients respond to aromatase inhibitors (AI), and many patients become unresponsive or relapse." | 2.76 | Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. ( Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC, 2011) |
| "Triple negative breast cancers experience the highest pCR rate of 30%." | 2.75 | A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. ( Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M, 2010) |
| "Of 200 consecutive breast cancer patients, 191 received the full package." | 2.75 | Multimodal prevention of pain, nausea and vomiting after breast cancer surgery. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2010) |
| "AI is effective in treating breast cancer and may be safely used preoperatively." | 2.73 | Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. ( Chow, LW; Lam, CK; Loo, WT; Toi, M; Yip, AY, 2008) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment." | 2.71 | Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. ( Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L, 2004) |
| "Celecoxib was administered at 400 mg/day during the entire course of radiotherapy." | 2.71 | Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. ( Bonomi, MR; Cabalar, ME; Castro, MA; Cerchietti, LC; Navigante, AH; Roth, BM, 2005) |
| "Despite advances in breast cancer treatment, mortality from breast cancer is still high." | 2.52 | Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review. ( Ch Yiannakopoulou, E, 2015) |
| "Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable." | 2.48 | Primary systemic therapy in HER2-amplified breast cancer: a clinical review. ( Bell, R; Khasraw, M, 2012) |
| "Although triple-negative breast cancer accounts for less than one-fifth of breast cancers, it has a higher rate of metastasis and mortality." | 1.91 | Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells. ( Hedayat, M; Jafari, R; Khezri, MR; Majidi Zolbanin, N; Malekinejad, H, 2023) |
| "Celecoxib analogue 4f is a promising multi-targeted lead for the design and synthesis of potent anticancer agents." | 1.72 | Design and Synthesis of Novel Celecoxib Analogues with Potential Cytotoxic and Pro-apoptotic Activity against Breast Cancer Cell Line MCF-7. ( Abdelhaleem, EF; El-Nassan, HB; Kassab, AE; Khalil, OM, 2022) |
| "In drug-resistant human breast cancer MCF-7/ADR cells, HPPDC nanoparticles significantly enhanced the cellular uptake of DOX through the endocytosis mediated by CD44/HA specific binding and the down-regulated P-gp expression induced by COX-2 inhibition, and thus notably increased the cytotoxicity and apoptosis-inducing activity of DOX." | 1.51 | pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. ( Guo, N; Li, C; Liu, Y; Wan, G; Wang, Y; Zhang, S; Zhang, T, 2019) |
| "The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy." | 1.51 | Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. ( Carpi, A; Ferrari, P; Morganti, R; Nicolini, A, 2019) |
| "In spite of the high incidence of breast cancer worldwide, there are few strategies for its chemoprevention, and they have limited adherence mainly due to their serious adverse effects." | 1.51 | Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer. ( de Brito, M; Lopes, LB; Mojeiko, G; Salata, GC, 2019) |
| "Finding a cure for breast cancer currently remains a medical challenge in due to the failure of common treatment methods to inhibit invasion and metastasis of cancer cells, which eventually leads to recurrence of breast cancer." | 1.48 | Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis. ( Chang, X; Cui, PF; He, YJ; Jiang, HL; Jin, QR; Qiao, JB; Xiao, Y; Xing, L; Yu, RY; Zhou, TJ, 2018) |
| "Treatment with celecoxib significantly decreased the induced tumor size and metastasis of the PyMT/Col1a1 tumors, such that their size was not different from the smaller PyMT tumors." | 1.43 | COX-2 modulates mammary tumor progression in response to collagen density. ( Esbona, K; Inman, D; Jeffery, J; Keely, P; Saha, S; Schedin, P; Wilke, L, 2016) |
| "Interestingly, human breast cancer tissue samples displayed high expression of OPG, PGE2 and fatty acid synthase (FASN)." | 1.43 | Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis. ( Goswami, S; Sharma-Walia, N, 2016) |
| "Inflammation is a potent promoter of tumor metastasis." | 1.42 | Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway. ( Bi, Y; Han, M; Jiang, M; Li, S; Xu, J; Xu, X, 2015) |
| "Here, we show that breast cancer cells can spontaneously disseminate into the CSF from brain lesions in mice in a COX-2-dependent manner and can escape from the CNS to systemic circulation." | 1.40 | COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation. ( Allen, JE; Dicker, DT; El-Deiry, WS; Glantz, MJ; Patel, AS; Prabhu, VV; Sheehan, JM, 2014) |
| "CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis." | 1.40 | Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. ( Anastasiadis, PZ; Assefnia, S; Brenner, M; Brown, ML; Byers, SW; Dakshanamurthy, S; Foley, DW; Guidry Auvil, JM; Haigh, D; Hampel, C; Kallakury, B; Shapiro, L; Uren, A, 2014) |
| "Refractoriness of invasive breast cancer is closely related with the vasculogenic mimicry (VM) channels, which exhibit highly drug resistance to conventional chemotherapies." | 1.40 | Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. ( Ju, RJ; Li, XT; Li, XY; Liu, L; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX; Zhao, WY; Zhou, J, 2014) |
| "Furthermore, breast cancer cells exposed to the involuting mammary microenvironment acquired prolymphangiogenic properties that contributed to peritumor lymphatic expansion, tumor size, invasion, and distant metastases." | 1.40 | Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. ( Betts, CB; Borges, VF; Guo, Q; Jindal, S; Kapoor, P; Lyons, TR; Martinson, HA; Schedin, P, 2014) |
| "This study showed that in NMU-induced mammary cancer in rats, the combination of resveratrol and celecoxib led to a significant reduction in all tumor parameters." | 1.40 | Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. ( Bojková, B; Ekmekcioglu, C; Fedoročko, P; Jäger, W; Jendželovský, R; Kajo, K; Kassayová, M; Kisková, T; Kokošová, N; Kubatka, P; Maier-Salamon, A; Mikeš, J; Orendáš, P; Papčová, Z; Rentsen, E; Svoboda, M; Thalhammer, T, 2014) |
| "Breast cancer is the most common malignancy in women, and many breast cancer patients fail conventional treatment strategies of chemotherapy, radiation, and antiestrogen therapy." | 1.38 | Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. ( Gao, JX; Liu, CM; Wang, XY; Wang, YX; Zhang, L, 2012) |
| "In murine breast cancer models, the two interferon-gamma (IFN-γ) inducible chemokines and CXC-chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by γ-interferon (CXCL9) and interferon-γ-inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes." | 1.38 | Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. ( Avril, S; Bronger, H; Cerny, C; Kiechle, M; Kraeft, S; Schmitt, M; Schwarz-Boeger, U; Stöckel, A, 2012) |
| "The prognosis of breast cancer in young women is influenced by reproductive history." | 1.37 | Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. ( Borges, VF; Conklin, MW; Eliceiri, KW; Keely, PJ; Lyons, TR; Marusyk, A; O'Brien, J; Schedin, P; Tan, AC, 2011) |
| "Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2." | 1.36 | Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model. ( Buttars, S; Done, SJ; Tran-Thanh, D; Wen, Y; Wilson, C, 2010) |
| "Celecoxib (50 microM) was found to significantly enhance the sensitivity of MCF-7 and JAR/VP16 cells to tamoxifen and etoposide, respectively, by inhibition of p170 expression and increase in intracellular accumulation of the drugs." | 1.35 | Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. ( Han, X; Lv, J; Shi, J; Sun, Y; Wang, S; Xia, W; Xu, S; Zhao, T, 2009) |
| "Celecoxib can inhibit cell proliferation, regulate cell cycle and induce apoptosis, but the underlying mechanisms are still unclear." | 1.35 | [Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway]. ( Li, J; Liu, LH; Sang, MX; Shan, BE; Wang, L; Zhang, C, 2009) |
| "While current breast cancer chemoprevention strategies using selective estrogen response modulators and aromatase inhibitors are quite successful, their effects are limited to hormonally responsive breast cancer." | 1.35 | Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. ( Gould, MN; Haag, JD; Lubet, RA; Mau, B; Woditschka, S, 2008) |
| "Celecoxib-treated A549 tumors had marginal reduction of total and perfused blood vessels compared with untreated controls." | 1.32 | Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. ( Chen, Y; Ding, I; Fenton, B; Finkelstein, J; Guo, M; Hu, D; Keng, P; Liang, L; Liu, W; Okunieff, P; Wang, W, 2003) |
| "Celecoxib-treated animals had less inflammation of the dermis compared with saline-treated controls." | 1.32 | Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor. ( Ding, I; Hu, D; Liang, L; Liu, W; Okunieff, P; Williams, JP, 2003) |
| "Celecoxib was administered i." | 1.31 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. ( Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 57 (40.43) | 29.6817 |
| 2010's | 74 (52.48) | 24.3611 |
| 2020's | 10 (7.09) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 3 |
| Zhou, J | 2 |
| Bensdorf, K | 1 |
| Zhang, H | 1 |
| Liu, H | 2 |
| Wang, Y | 4 |
| Qian, H | 1 |
| Zhang, Y | 1 |
| Wellner, A | 1 |
| Rubner, G | 1 |
| Huang, W | 1 |
| Guo, C | 1 |
| Gust, R | 1 |
| Bardaweel, SK | 1 |
| Dahabiyeh, LA | 1 |
| Akileh, BM | 1 |
| Shalabi, DD | 1 |
| AlHiary, AK | 1 |
| Pawling, J | 1 |
| Dennis, JW | 1 |
| Rahman, AMA | 1 |
| Gallardo-Pérez, JC | 1 |
| de Guevara, AA | 1 |
| García-Amezcua, MA | 1 |
| Robledo-Cadena, DX | 1 |
| Pacheco-Velázquez, SC | 1 |
| Belmont-Díaz, JA | 1 |
| Vargas-Navarro, JL | 1 |
| Moreno-Sánchez, R | 1 |
| Rodríguez-Enríquez, S | 1 |
| Giacomini, I | 1 |
| Quagliariello, V | 1 |
| Ragazzi, E | 1 |
| Montopoli, M | 1 |
| Geyer, CE | 1 |
| Bandos, H | 1 |
| Rastogi, P | 1 |
| Jacobs, SA | 1 |
| Robidoux, A | 1 |
| Fehrenbacher, L | 1 |
| Ward, PJ | 1 |
| Polikoff, J | 1 |
| Brufsky, AM | 1 |
| Provencher, L | 1 |
| Paterson, AHG | 1 |
| Hamm, JT | 1 |
| Carolla, RL | 1 |
| Baez-Diaz, L | 1 |
| Julian, TB | 1 |
| Swain, SM | 1 |
| Mamounas, EP | 1 |
| Wolmark, N | 1 |
| Abdelhaleem, EF | 1 |
| Kassab, AE | 1 |
| El-Nassan, HB | 1 |
| Khalil, OM | 1 |
| Hedayat, M | 1 |
| Khezri, MR | 1 |
| Jafari, R | 1 |
| Malekinejad, H | 1 |
| Majidi Zolbanin, N | 1 |
| Zhang, T | 2 |
| Li, Y | 1 |
| Li, C | 3 |
| Wan, G | 2 |
| Chen, B | 1 |
| Zhang, S | 2 |
| Guo, N | 1 |
| Liu, Y | 2 |
| Nicolini, A | 1 |
| Ferrari, P | 1 |
| Morganti, R | 1 |
| Carpi, A | 1 |
| Sun, J | 1 |
| Li, J | 3 |
| Liu, Q | 2 |
| Jiang, M | 3 |
| Yang, M | 1 |
| Zhan, S | 1 |
| Qiu, T | 1 |
| He, K | 1 |
| Zhang, X | 1 |
| Alqahtani, AM | 1 |
| Chidambaram, K | 1 |
| Pino-Figueroa, A | 1 |
| Chandrasekaran, B | 1 |
| Dhanaraj, P | 1 |
| Venkatesan, K | 1 |
| Coombes, RC | 1 |
| Tovey, H | 1 |
| Kilburn, L | 1 |
| Mansi, J | 1 |
| Palmieri, C | 1 |
| Bartlett, J | 1 |
| Hicks, J | 1 |
| Makris, A | 1 |
| Evans, A | 1 |
| Loibl, S | 1 |
| Denkert, C | 1 |
| Murray, E | 1 |
| Grieve, R | 1 |
| Coleman, R | 1 |
| Borley, A | 1 |
| Schmidt, M | 1 |
| Rautenberg, B | 1 |
| Kunze, CA | 1 |
| Rhein, U | 1 |
| Mehta, K | 1 |
| Mousa, K | 1 |
| Dibble, T | 1 |
| Lu, XL | 1 |
| von Minckwitz, G | 1 |
| Bliss, JM | 1 |
| Elzoghby, AO | 2 |
| Mostafa, SK | 1 |
| Helmy, MW | 2 |
| ElDemellawy, MA | 1 |
| Sheweita, SA | 1 |
| Wang, G | 1 |
| Zhang, L | 2 |
| Huang, S | 1 |
| Zhao, X | 2 |
| Friedrich, M | 1 |
| Reichert, K | 1 |
| Woeste, A | 1 |
| Polack, S | 1 |
| Fischer, D | 1 |
| Hoellen, F | 1 |
| Rody, A | 1 |
| Köster, F | 1 |
| Thill, M | 1 |
| DE Cremoux, P | 2 |
| Hamy, AS | 3 |
| Lehmann-Che, J | 1 |
| Scott, V | 1 |
| Sigal, B | 1 |
| Mathieu, MC | 3 |
| Bertheau, P | 3 |
| Guinebretière, JM | 3 |
| Pierga, JY | 5 |
| Giacchetti, S | 3 |
| Brain, E | 5 |
| Marty, M | 5 |
| Asselain, B | 3 |
| Spyratos, F | 1 |
| Bièche, I | 2 |
| Strasser-Weippl, K | 1 |
| Higgins, MJ | 1 |
| Chapman, JW | 1 |
| Ingle, JN | 1 |
| Sledge, GW | 1 |
| Budd, GT | 1 |
| Ellis, MJ | 1 |
| Pritchard, KI | 1 |
| Clemons, MJ | 1 |
| Badovinac-Crnjevic, T | 1 |
| Han, L | 1 |
| Gelmon, KA | 1 |
| Rabaglio, M | 1 |
| Elliott, C | 1 |
| Shepherd, LE | 1 |
| Goss, PE | 1 |
| Hawk, E | 1 |
| Maresso, KC | 1 |
| Brown, P | 1 |
| Ghasemi, A | 1 |
| Danesh, B | 1 |
| Yazdani-Charati, J | 1 |
| Hosseinimehr, SJ | 1 |
| Yu, RY | 1 |
| Xing, L | 1 |
| Cui, PF | 1 |
| Qiao, JB | 1 |
| He, YJ | 1 |
| Chang, X | 1 |
| Zhou, TJ | 1 |
| Jin, QR | 1 |
| Jiang, HL | 1 |
| Xiao, Y | 1 |
| AbdElhamid, AS | 1 |
| Zayed, DG | 1 |
| Ebrahim, SM | 1 |
| Bahey-El-Din, M | 1 |
| Zein-El-Dein, EA | 1 |
| El-Gizawy, SA | 1 |
| Tury, S | 2 |
| Wang, X | 1 |
| Gao, J | 1 |
| Pistilli, B | 1 |
| Espié, M | 3 |
| Benchimol, G | 1 |
| Laas, E | 1 |
| Laé, M | 1 |
| Aouchiche, B | 1 |
| Edelman, M | 1 |
| Reyal, F | 2 |
| Moradi, K | 1 |
| Barneh, F | 1 |
| Irian, S | 1 |
| Amini, M | 1 |
| Moradpoor, R | 1 |
| Amanzadeh, A | 1 |
| Choopani, S | 1 |
| Rahimi, H | 1 |
| Ghodselahi, T | 1 |
| Boujar, MM | 1 |
| Salimi, M | 1 |
| Mojeiko, G | 1 |
| de Brito, M | 1 |
| Salata, GC | 1 |
| Lopes, LB | 1 |
| Johansson, H | 2 |
| Aristarco, V | 2 |
| Gandini, S | 2 |
| Gjerde, J | 1 |
| Macis, D | 2 |
| Guerrieri-Gonzaga, A | 2 |
| Serrano, D | 2 |
| Lazzeroni, M | 2 |
| Rajasekaran, A | 1 |
| Williard, CV | 1 |
| Mellgren, G | 1 |
| DeCensi, A | 2 |
| Bonanni, B | 2 |
| Ahmed, S | 1 |
| Khan, H | 1 |
| Fratantonio, D | 1 |
| Hasan, MM | 1 |
| Sharifi, S | 1 |
| Fathi, N | 1 |
| Ullah, H | 1 |
| Rastrelli, L | 1 |
| Üner, M | 1 |
| Yener, G | 1 |
| Ergüven, M | 1 |
| Perroud, HA | 4 |
| Rico, MJ | 4 |
| Alasino, CM | 3 |
| Queralt, F | 3 |
| Mainetti, LE | 3 |
| Pezzotto, SM | 3 |
| Rozados, VR | 4 |
| Scharovsky, OG | 4 |
| Brandão, RD | 1 |
| Veeck, J | 1 |
| Van de Vijver, KK | 1 |
| Lindsey, P | 1 |
| de Vries, B | 1 |
| van Elssen, CH | 1 |
| Blok, MJ | 1 |
| Keymeulen, K | 1 |
| Ayoubi, T | 1 |
| Smeets, HJ | 1 |
| Tjan-Heijnen, VC | 1 |
| Hupperets, PS | 1 |
| Majumder, M | 1 |
| Xin, X | 1 |
| Lala, PK | 1 |
| Kumar, BN | 1 |
| Rajput, S | 1 |
| Dey, KK | 1 |
| Parekh, A | 1 |
| Das, S | 1 |
| Mazumdar, A | 1 |
| Mandal, M | 1 |
| Allen, JE | 1 |
| Patel, AS | 1 |
| Prabhu, VV | 1 |
| Dicker, DT | 1 |
| Sheehan, JM | 1 |
| Glantz, MJ | 1 |
| El-Deiry, WS | 1 |
| Assefnia, S | 1 |
| Dakshanamurthy, S | 1 |
| Guidry Auvil, JM | 1 |
| Hampel, C | 1 |
| Anastasiadis, PZ | 1 |
| Kallakury, B | 1 |
| Uren, A | 1 |
| Foley, DW | 1 |
| Brown, ML | 1 |
| Shapiro, L | 1 |
| Brenner, M | 1 |
| Haigh, D | 1 |
| Byers, SW | 1 |
| Generali, D | 1 |
| Buffa, FM | 1 |
| Deb, S | 1 |
| Cummings, M | 1 |
| Reid, LE | 1 |
| Taylor, M | 1 |
| Andreis, D | 1 |
| Allevi, G | 1 |
| Ferrero, G | 1 |
| Byrne, D | 1 |
| Martinotti, M | 1 |
| Bottini, A | 1 |
| Harris, AL | 1 |
| Lakhani, SR | 1 |
| Fox, SB | 1 |
| Ju, RJ | 1 |
| Li, XT | 1 |
| Shi, JF | 1 |
| Li, XY | 1 |
| Sun, MG | 1 |
| Zeng, F | 1 |
| Liu, L | 1 |
| Zhang, CX | 1 |
| Zhao, WY | 1 |
| Lu, WL | 1 |
| Wong, TY | 1 |
| Li, F | 1 |
| Lin, SM | 1 |
| Chan, FL | 1 |
| Chen, S | 1 |
| Leung, LK | 1 |
| Rosas, C | 1 |
| Sinning, M | 1 |
| Ferreira, A | 1 |
| Fuenzalida, M | 1 |
| Lemus, D | 1 |
| Lyons, TR | 2 |
| Borges, VF | 2 |
| Betts, CB | 1 |
| Guo, Q | 1 |
| Kapoor, P | 1 |
| Martinson, HA | 1 |
| Jindal, S | 1 |
| Schedin, P | 3 |
| Kisková, T | 1 |
| Jendželovský, R | 1 |
| Rentsen, E | 1 |
| Maier-Salamon, A | 1 |
| Kokošová, N | 1 |
| Papčová, Z | 1 |
| Mikeš, J | 1 |
| Orendáš, P | 1 |
| Bojková, B | 1 |
| Kubatka, P | 1 |
| Svoboda, M | 1 |
| Kajo, K | 1 |
| Fedoročko, P | 1 |
| Jäger, W | 1 |
| Ekmekcioglu, C | 1 |
| Kassayová, M | 1 |
| Thalhammer, T | 1 |
| Liu, S | 1 |
| Zhao, Q | 1 |
| Li, S | 2 |
| Peng, Y | 1 |
| Zhang, P | 1 |
| Han, M | 3 |
| Ch Yiannakopoulou, E | 1 |
| Cao, J | 1 |
| Yang, X | 1 |
| Li, WT | 1 |
| Zhao, CL | 1 |
| Lv, SJ | 1 |
| Xu, X | 1 |
| Bi, Y | 1 |
| Xu, J | 1 |
| Jeon, YW | 1 |
| Ahn, YE | 1 |
| Chung, WS | 1 |
| Choi, HJ | 1 |
| Suh, YJ | 2 |
| Mohammadinejad, P | 1 |
| Arya, P | 1 |
| Esfandbod, M | 1 |
| Kaviani, A | 1 |
| Najafi, M | 1 |
| Kashani, L | 1 |
| Zeinoddini, A | 1 |
| Emami, SA | 1 |
| Akhondzadeh, S | 1 |
| Feroce, I | 1 |
| Pruneri, G | 1 |
| Pagani, G | 1 |
| Toesca, A | 1 |
| Caldarella, P | 1 |
| Esbona, K | 1 |
| Inman, D | 1 |
| Saha, S | 1 |
| Jeffery, J | 1 |
| Wilke, L | 1 |
| Keely, P | 1 |
| Goswami, S | 1 |
| Sharma-Walia, N | 1 |
| Sangaletti, S | 1 |
| Tripodo, C | 1 |
| Santangelo, A | 1 |
| Castioni, N | 1 |
| Portararo, P | 1 |
| Gulino, A | 1 |
| Botti, L | 1 |
| Parenza, M | 1 |
| Cappetti, B | 1 |
| Orlandi, R | 1 |
| Tagliabue, E | 1 |
| Chiodoni, C | 1 |
| Colombo, MP | 1 |
| Sagara, A | 1 |
| Igarashi, K | 1 |
| Otsuka, M | 1 |
| Karasawa, T | 1 |
| Gotoh, N | 1 |
| Narita, M | 2 |
| Kuzumaki, N | 1 |
| Kato, Y | 1 |
| Becette, V | 1 |
| Assayag, F | 1 |
| Vacher, S | 1 |
| Benoist, C | 1 |
| Kamal, M | 1 |
| Marangoni, E | 1 |
| Lerebours, F | 2 |
| Callens, C | 1 |
| van Helmond, N | 1 |
| Steegers, MA | 1 |
| Filippini-de Moor, GP | 1 |
| Vissers, KC | 1 |
| Wilder-Smith, OH | 1 |
| Delaloge, S | 3 |
| Berger, F | 1 |
| Sigal-Zafrani, B | 2 |
| Saghatchian, M | 1 |
| Mazouni, C | 1 |
| Tembo, O | 1 |
| Chow, LW | 9 |
| Yip, AY | 3 |
| Loo, WT | 4 |
| Lam, CK | 1 |
| Toi, M | 8 |
| Gärtner, R | 3 |
| Callesen, T | 3 |
| Kroman, N | 3 |
| Kehlet, H | 3 |
| Boneberg, EM | 1 |
| Legler, DF | 1 |
| Senn, HJ | 1 |
| Fürstenberger, G | 1 |
| Niu, G | 1 |
| Liao, Z | 1 |
| Cai, L | 1 |
| Wei, R | 1 |
| Sun, L | 2 |
| Qin, W | 3 |
| Zhu, W | 1 |
| Hewett, JE | 3 |
| Rottinghaus, G | 2 |
| Chen, YC | 2 |
| Flynn, JT | 4 |
| Kliethermes, B | 1 |
| Mannello, F | 1 |
| Sauter, ER | 4 |
| Falandry, C | 1 |
| Debled, M | 1 |
| Bachelot, T | 3 |
| Delozier, T | 1 |
| Crétin, J | 1 |
| Romestaing, P | 1 |
| Mille, D | 1 |
| You, B | 1 |
| Mauriac, L | 1 |
| Pujade-Lauraine, E | 1 |
| Freyer, G | 1 |
| Piskunova, TS | 1 |
| Suspitsin, EN | 1 |
| Sokolenko, AP | 1 |
| Zabezhinskiĭ, MA | 1 |
| Imianitov, EI | 1 |
| Semenchenko, AV | 1 |
| Anisimov, VN | 1 |
| Xia, W | 1 |
| Zhao, T | 1 |
| Lv, J | 1 |
| Xu, S | 1 |
| Shi, J | 1 |
| Wang, S | 1 |
| Han, X | 1 |
| Sun, Y | 1 |
| Wang, L | 2 |
| Liu, LH | 1 |
| Shan, BE | 1 |
| Zhang, C | 1 |
| Sang, MX | 1 |
| Kim, S | 1 |
| Kim, SH | 1 |
| Hur, SM | 1 |
| Lee, SK | 1 |
| Kim, WW | 1 |
| Kim, JS | 1 |
| Kim, JH | 1 |
| Choe, JH | 1 |
| Nam, SJ | 1 |
| Lee, JE | 1 |
| Yang, JH | 1 |
| Glück, S | 2 |
| Bidard, FC | 1 |
| Mathiot, C | 1 |
| Giachetti, S | 1 |
| Tran-Thanh, D | 1 |
| Buttars, S | 1 |
| Wen, Y | 1 |
| Wilson, C | 1 |
| Done, SJ | 1 |
| Bundred, NJ | 2 |
| Cramer, A | 1 |
| Morris, J | 1 |
| Renshaw, L | 1 |
| Cheung, KL | 1 |
| Flint, P | 1 |
| Johnson, R | 1 |
| Young, O | 1 |
| Landberg, G | 1 |
| Grassby, S | 1 |
| Turner, L | 1 |
| Baildam, A | 1 |
| Barr, L | 1 |
| Dixon, JM | 1 |
| Chen, C | 1 |
| Shen, HL | 1 |
| Yang, J | 2 |
| Chen, QY | 1 |
| Xu, WL | 1 |
| Kalalinia, F | 1 |
| Elahian, F | 1 |
| Behravan, J | 1 |
| Singh, B | 2 |
| Cook, KR | 1 |
| Vincent, L | 1 |
| Hall, CS | 1 |
| Martin, C | 1 |
| Lucci, A | 3 |
| Spielmann, M | 1 |
| Savignoni, A | 1 |
| Irving, LR | 1 |
| Tai, K | 1 |
| Martin, LA | 1 |
| Davies, GL | 1 |
| Weigel, MT | 1 |
| Betambeau, N | 1 |
| Hills, MJ | 1 |
| Salter, J | 1 |
| Walsh, G | 1 |
| A'Hern, R | 1 |
| Dowsett, M | 1 |
| Ashok, V | 1 |
| Dash, C | 1 |
| Rohan, TE | 1 |
| Sprafka, JM | 1 |
| Terry, PD | 1 |
| Meyskens, FL | 1 |
| McLaren, CE | 1 |
| Bocca, C | 1 |
| Bozzo, F | 1 |
| Bassignana, A | 1 |
| Miglietta, A | 1 |
| Chu, WP | 1 |
| Tournoux-Facon, C | 1 |
| De Rycke, Y | 1 |
| Tubert-Bitter, P | 1 |
| Lustberg, MB | 1 |
| Povoski, SP | 1 |
| Zhao, W | 1 |
| Ziegler, RM | 1 |
| Sugimoto, Y | 1 |
| Ruppert, AS | 1 |
| Lehman, AM | 1 |
| Shiels, DR | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Layman, RM | 1 |
| Brueggemeier, RW | 2 |
| Shapiro, CL | 2 |
| Chanplakorn, N | 1 |
| Chanplakorn, P | 1 |
| Suzuki, T | 1 |
| Ono, K | 1 |
| Chan, MS | 1 |
| Wing, L | 1 |
| Yiu, CC | 1 |
| Sasano, H | 1 |
| El-Awady, RA | 1 |
| Saleh, EM | 1 |
| Ezz, M | 1 |
| Elsayed, AM | 1 |
| Liu, B | 1 |
| Wen, JK | 1 |
| Li, BH | 1 |
| Fang, XM | 1 |
| Wang, JJ | 1 |
| Zhang, YP | 1 |
| Shi, CJ | 1 |
| Zhang, DQ | 1 |
| O'Brien, J | 2 |
| Conklin, MW | 1 |
| Keely, PJ | 1 |
| Eliceiri, KW | 1 |
| Marusyk, A | 1 |
| Tan, AC | 1 |
| Liu, XJ | 1 |
| Chen, YJ | 1 |
| Wang, J | 1 |
| Wang, YX | 1 |
| Gao, JX | 1 |
| Wang, XY | 1 |
| Liu, CM | 1 |
| Matar, P | 1 |
| Zacarías Fluck, MF | 1 |
| Fernández Zenóbi, MV | 1 |
| Roggero, EA | 1 |
| Gervasoni, SI | 1 |
| Rossa, A | 1 |
| Sánchez, AM | 1 |
| Celoria, GC | 1 |
| Font, MT | 1 |
| Bronger, H | 1 |
| Kraeft, S | 1 |
| Schwarz-Boeger, U | 1 |
| Cerny, C | 1 |
| Stöckel, A | 1 |
| Avril, S | 1 |
| Kiechle, M | 1 |
| Schmitt, M | 1 |
| Thomas, S | 1 |
| Sharma, N | 1 |
| Golden, EB | 1 |
| Cho, H | 1 |
| Agarwal, P | 1 |
| Gaffney, KJ | 1 |
| Petasis, NA | 1 |
| Chen, TC | 1 |
| Hofman, FM | 1 |
| Louie, SG | 1 |
| Schönthal, AH | 1 |
| Khasraw, M | 1 |
| Bell, R | 1 |
| Tung, SY | 1 |
| Ng, TY | 1 |
| Im, SA | 1 |
| Lee, MH | 1 |
| Chen, Y | 1 |
| Wang, W | 1 |
| Keng, P | 1 |
| Finkelstein, J | 1 |
| Hu, D | 2 |
| Liang, L | 2 |
| Guo, M | 1 |
| Fenton, B | 1 |
| Okunieff, P | 2 |
| Ding, I | 2 |
| Williams, JP | 1 |
| Wong, JL | 2 |
| Fife, RS | 1 |
| Stott, B | 1 |
| Carr, RE | 1 |
| Kammerer, S | 1 |
| Arun, B | 1 |
| Goss, P | 1 |
| Dang, CT | 1 |
| Dannenberg, AJ | 2 |
| Subbaramaiah, K | 2 |
| Dickler, MN | 1 |
| Moasser, MM | 1 |
| Seidman, AD | 1 |
| D'Andrea, GM | 1 |
| Theodoulou, M | 1 |
| Panageas, KS | 1 |
| Norton, L | 1 |
| Hudis, CA | 1 |
| Guastalla, JP | 2 |
| Ray-Coquard, I | 2 |
| Zhu, L | 2 |
| Guan, XY | 1 |
| Prosperi, JR | 2 |
| Mallery, SR | 1 |
| Kigerl, KA | 1 |
| Erfurt, AA | 1 |
| Robertson, FM | 2 |
| Lawson, KA | 1 |
| Simmons-Menchaca, M | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Zielinski, SL | 1 |
| Schlatter, L | 2 |
| Hewett, J | 1 |
| Koivunen, D | 1 |
| Basu, GD | 3 |
| Pathangey, LB | 2 |
| Tinder, TL | 2 |
| Lagioia, M | 1 |
| Gendler, SJ | 2 |
| Mukherjee, P | 3 |
| Cerchietti, LC | 1 |
| Bonomi, MR | 1 |
| Navigante, AH | 1 |
| Castro, MA | 1 |
| Cabalar, ME | 1 |
| Roth, BM | 1 |
| Thompson, CA | 1 |
| Kucab, JE | 2 |
| Lee, C | 1 |
| Chen, CS | 3 |
| Zhu, J | 1 |
| Gilks, CB | 1 |
| Cheang, M | 1 |
| Huntsman, D | 1 |
| Yorida, E | 1 |
| Emerman, J | 1 |
| Pollak, M | 2 |
| Dunn, SE | 3 |
| Andrews, HN | 1 |
| Habibi, G | 1 |
| Chada, S | 1 |
| McKenzie, T | 1 |
| Swisher, SG | 1 |
| Hunt, KK | 1 |
| Hahn, T | 1 |
| Alvarez, I | 1 |
| Kobie, JJ | 1 |
| Ramanathapuram, L | 1 |
| Dial, S | 1 |
| Fulton, A | 1 |
| Besselsen, D | 1 |
| Walker, E | 1 |
| Akporiaye, ET | 1 |
| Wai, CC | 1 |
| Lui, EL | 1 |
| Cheng, CW | 1 |
| Ueno, T | 1 |
| Tseng, PH | 1 |
| Wang, YC | 1 |
| Weng, SC | 1 |
| Weng, JR | 1 |
| Chen, CY | 1 |
| Haupt, S | 1 |
| Kleinstern, J | 1 |
| Haupt, Y | 1 |
| Rubinstein, A | 1 |
| Iohom, G | 1 |
| Abdalla, H | 1 |
| Szarvas, S | 1 |
| Larney, V | 1 |
| Buckley, E | 1 |
| Butler, M | 1 |
| Shorten, GD | 1 |
| Canney, PA | 1 |
| Machin, MA | 1 |
| Curto, J | 1 |
| van Wijngaarden, J | 1 |
| van Beek, E | 1 |
| van Rossum, G | 1 |
| van der Bent, C | 1 |
| Hoekman, K | 1 |
| van der Pluijm, G | 1 |
| van der Pol, MA | 1 |
| Broxterman, HJ | 1 |
| van Hinsbergh, VW | 1 |
| Löwik, CW | 1 |
| Liang, WS | 1 |
| Stephan, DA | 1 |
| Wegener, LT | 1 |
| Conley, CR | 1 |
| Pockaj, BA | 1 |
| Talmadge, JE | 1 |
| Hood, KC | 1 |
| Zobel, LC | 1 |
| Shafer, LR | 1 |
| Coles, M | 1 |
| Toth, B | 1 |
| Barnes, NL | 1 |
| Warnberg, F | 1 |
| Farnie, G | 1 |
| White, D | 1 |
| Jiang, W | 1 |
| Anderson, E | 1 |
| Fournier, LS | 1 |
| Novikov, V | 1 |
| Lucidi, V | 1 |
| Fu, Y | 1 |
| Miller, T | 1 |
| Floyd, E | 1 |
| Shames, DM | 1 |
| Brasch, RC | 1 |
| Sugimoto, T | 1 |
| Bartholomeusz, C | 1 |
| Tari, AM | 1 |
| Ueno, NT | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Tfayli, A | 1 |
| Kojouri, K | 1 |
| Kesserwan, C | 1 |
| Jafari, M | 1 |
| Ozer, H | 1 |
| Ruhlen, RL | 1 |
| Woditschka, S | 1 |
| Haag, JD | 1 |
| Mau, B | 1 |
| Lubet, RA | 1 |
| Gould, MN | 1 |
| Dirix, LY | 1 |
| Ignacio, J | 1 |
| Nag, S | 1 |
| Bapsy, P | 1 |
| Gomez, H | 1 |
| Raghunadharao, D | 1 |
| Paridaens, R | 1 |
| Jones, S | 1 |
| Falcon, S | 1 |
| Carpentieri, M | 1 |
| Abbattista, A | 1 |
| Lobelle, JP | 1 |
| Beitz, J | 1 |
| Howe, LR | 1 |
| Brown, AM | 1 |
| Blumenthal, RD | 1 |
| Waskewich, C | 1 |
| Goldenberg, DM | 1 |
| Lew, W | 1 |
| Flefleh, C | 1 |
| Burton, J | 1 |
| Kawamori, T | 1 |
| Wakabayashi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer[NCT00087178] | Phase 3 | 2,722 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients[NCT02429427] | Phase 3 | 2,639 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573] | Phase 3 | 7,576 participants (Actual) | Interventional | 2003-06-06 | Completed | ||
| A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer[NCT01041781] | Phase 3 | 313 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to DSMB recommendation) | ||
| Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer[NCT01695226] | Phase 2 | 0 participants | Interventional | 2004-02-29 | Completed | ||
| Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial[NCT01904266] | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study[NCT04875559] | 236 participants (Actual) | Observational [Patient Registry] | 2021-04-19 | Completed | |||
| Oral L-arginine Supplementation in Patients With Non-resectable Brain Metastases Treated With Radiation Therapy With Palliative Intent[NCT02844387] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients with at least one grade 2 or higher adverse event reported (NCT00087178)
Timeframe: 9 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | 28.5 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 45.0 |
Change in LVEF from randomization to 12 months (NCT00087178)
Timeframe: 12 months
| Intervention | Change in percent ejection fraction (Mean) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | -2.61 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | -2.65 |
Percentage of patients free from DFS event. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer (NCT00087178)
Timeframe: 9 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | 80.1 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 79.4 |
Percentage of patients with distant recurrence (NCT00087178)
Timeframe: 9 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | 8.3 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 7.2 |
Percent with post chemotherapy amenorrhea (NCT00087178)
Timeframe: 18 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | 59.1 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 67.4 |
Percentage of patients with local-regional recurrence or distant recurrence (NCT00087178)
Timeframe: 9 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | 10.8 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 10.4 |
Percentage of patients alive (NCT00087178)
Timeframe: 9 years
| Intervention | percentage of participants alive (Number) |
|---|---|
| Arm 1: Adriamycin + Cyclophosphamide | 89.8 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 89.9 |
Functional Assessment of Cancer Therapy (FACT-B) trial outcome index (TOI) score. FACT-B TOI score ranges from 0 to 92, with a higher score indicating better QOL. (NCT00087178)
Timeframe: 12 months
| Intervention | score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Score day 1 cycle 4 | Score 6 months | Score 12 months | |
| Arm 1: Adriamycin + Cyclophosphamide | 61.7 | 69.2 | 71.7 |
| Arm 2: Fluorouracil + Epirubicin + Cyclophosphamide | 60.3 | 66.9 | 71.1 |
Number of deaths recorded as having cardiovascular involvement are reported by treatment group. (NCT02429427)
Timeframe: Patients are followed up to 10 years, any deaths within this timeframe with cardiovascular involvement reported are included in the analysis.
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib | 6 |
| Placebo | 5 |
Any malignant contralateral breast disease will be included and recorded as a second primary (NCT02429427)
Timeframe: From randomisation until a second primary breast cancer is diagnosed. Patients will be followed up to 10 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib | 19 |
| Placebo | 12 |
From time of randomisation to the date of first event; with events contributing to the analysis defined as loco-regional and distant breast cancer recurrence, new primary breast cancer (ipsilateral or contralateral) and death without disease relapse (intercurrent death) (NCT02429427)
Timeframe: Patients will be followed up to 10 years. DFS will be calculated from date of randomization until the date of first documented DFS event, this will be assessed at 2 and 5 years
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| 2 Year DFS rate | 5 Year DFS rate | |
| Celecoxib | 91 | 84 |
| Placebo | 90 | 83 |
First local recurrence and first distant recurrence will be recorded on separate parts of the CRF. In the event of local progression, all patients must be followed up for distant recurrence, second malignancy and survival. Similarly in the case of second malignancy, the appropriate CRF should be completed and patients should REACT Protocol, Version 39, dated 01.11.2016 Page 34 of 48 continue to be followed for disease progression and where possible the relation of any subsequent disease progression and/or death due to the primary or second cancer should be established. (NCT02429427)
Timeframe: Date of randomisation until the date of death from any cause or censored at the date the patient was last seen alive, this will be assessed at 2 and 5 years
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| 2 Year | 5 Year | |
| Celecoxib | 97 | 90 |
| Placebo | 96 | 91 |
Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 358 |
| Anastrozole | 354 |
Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 157 |
| Anastrozole | 164 |
Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Exemestane | 88 |
| Anastrozole | 89 |
Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Exemestane | 92 |
| Anastrozole | 92 |
The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 61.04 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 55.06 |
Overall survival time is defined as the time from randomization to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 11.4 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 12.5 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the first quartile (Q1, 10.09). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q1 | 7.7 |
| PGE-M >= Q1 | 4.9 |
prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q2, 15.38). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q2 | 6.2 |
| PGE-M >= Q2 | 4.2 |
Prognostic value of urinary prostaglandin metabolites (PGE-M) levels for worse PFS for patients who had baseline urinary PGE-M above/below the median quartile (Q3, 27.86). Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| PGE-M < Q3 | 6.0 |
| PGE-M >= Q3 | 3.0 |
Progression free survival (PFS) is defined as the time from the date of randomization to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator. (NCT01041781)
Timeframe: Time between randomization and disease relapse or death from any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 5.16 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 5.26 |
The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test (NCT01041781)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Arm I (Arm A: Celecoxib + Standard Chemotherapy) | 40 |
| Arm II (Arm B: Placebo + Standard Chemotherapy) | 35 |
8 reviews available for celecoxib and Breast Cancer
| Article | Year |
|---|---|
Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2019 |
Interaction of Salicylates and the Other Nonsteroidal Anti-Inflammatory Agents With Breast Cancer Endocrine Treatment: Systematic Review.
Topics: Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Aromatase | 2015 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2012 |
The role of COX-2 inhibition in breast cancer treatment and prevention.
Topics: Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Breast Neoplasms; Celecoxib; Clinical T | 2004 |
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials].
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; | 2004 |
[Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase; Breast Neoplasms | 2004 |
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Topics: Animals; Breast Neoplasms; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2001 |
38 trials available for celecoxib and Breast Cancer
| Article | Year |
|---|---|
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ce | 2021 |
Topics: Adult; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Gene Expr | 2018 |
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Combined Modali | 2018 |
Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecox | 2018 |
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.
Topics: Aged; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase; Bre | 2020 |
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2013 |
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Celecoxib; Cyclo | 2013 |
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplas | 2014 |
Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial.
Topics: Analgesics; Antidepressive Agents; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Cycloox | 2015 |
Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Celecoxib; Cell Pr | 2016 |
Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2016 |
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; | 2016 |
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemothera | 2017 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2008 |
uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast; Breast Neoplasms; Celecoxib; Dinoprostone; Female; Humans; M | 2008 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase I | 2009 |
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Bre | 2010 |
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Biopsy; Breast Neoplasms; Celecoxib; Cell | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
Topics: Androstadienes; Animals; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bo | 2011 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular | 2011 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplas | 2011 |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide | 2013 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Topics: Androstadienes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2003 |
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breas | 2004 |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 2004 |
Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer.
Topics: Adult; Aged; Biomarkers; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Femal | 2004 |
Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Celecoxib; Combined Modality Therapy; Cyclooxygenase | 2005 |
Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Chol | 2005 |
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibi | 2006 |
The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
Topics: Acetaminophen; Adult; Aged; Analgesia; Anxiety; Breast Neoplasms; Bupivacaine; Celecoxib; Chronic Di | 2006 |
A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celec | 2006 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women.
Topics: Adult; Aged; Aged, 80 and over; Body Fluids; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; | 2008 |
Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area | 2008 |
95 other studies available for celecoxib and Breast Cancer
| Article | Year |
|---|---|
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell S | 2011 |
Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; | 2022 |
Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells.
Topics: Adenosine Triphosphate; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Epithelial-Mesenchymal Transi | 2022 |
Letter to Editor on the paper entitled "Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer".
Topics: Breast Neoplasms; Celecoxib; Curcumin; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Femal | 2021 |
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemoth | 2022 |
Design and Synthesis of Novel Celecoxib Analogues with Potential Cytotoxic and Pro-apoptotic Activity against Breast Cancer Cell Line MCF-7.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; | 2022 |
Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Celecoxib; Cell Line, Tumor; Fem | 2023 |
A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Topics: Alginates; Animals; Antineoplastic Agents; Benzoic Acid; Breast Neoplasms; Celecoxib; Cell Adhesion; | 2019 |
pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Topics: Animals; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Delayed-Action Preparations; Doxo | 2019 |
Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Topics: Adult; Aged; alpha-Tocopherol; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Colonic Neoplasms | 2019 |
Tuning mPEG-PLA/vitamin E-TPGS-based mixed micelles for combined celecoxib/honokiol therapy for breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Breast Neoplasms; Celecoxib; Lignans | 2020 |
Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cell Proliferation; Cel | 2021 |
Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Carriers; Drug Combinations; Femal | 2017 |
Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway.
Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Caspase 3; Celecoxib; Cell Cycle Checkpo | 2017 |
Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
Topics: Apoptosis; Breast Neoplasms; Calcitriol; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; | 2018 |
NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Aspirin; Breast Neoplasms; Celecoxib; | 2018 |
Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Breast Neoplasms; Brefeldin A; C | 2018 |
Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer.
Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Female; Humans; Hyaluron | 2018 |
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Celecoxi | 2019 |
Two Novel Tri-Aryl Derivatives Attenuate the Invasion-Promoting Effects of Stromal Mesenchymal Stem Cells on Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Dose-Respon | 2019 |
Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer.
Topics: Administration, Cutaneous; Animals; Breast Neoplasms; Celecoxib; Chemistry, Pharmaceutical; Chemopre | 2019 |
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia.
Topics: Breast Neoplasms; Celecoxib; Colloids; Drug Carriers; Female; HL-60 Cells; Humans; Leukemia, Myeloid | 2019 |
A practical and sensitive method of quantitating lymphangiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 In | 2013 |
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Blotting, Western; | 2013 |
COX-2 drives metastatic breast cells from brain lesions into the cerebrospinal fluid and systemic circulation.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cycl | 2014 |
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Breast Neoplas | 2014 |
Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Dr | 2014 |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Topics: Animals; Apoptosis; Aromatase; Aspirin; Body Weight; Breast Neoplasms; Celecoxib; Cell Cycle; Cycloo | 2014 |
Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Breast Neoplas | 2014 |
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.
Topics: Animals; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Female | 2014 |
Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogens; Celecoxib; Chemoprevention; Drug Sy | 2014 |
Vascular endothelial growth factor plays a critical role in the formation of the pre-metastatic niche via prostaglandin E2.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Fema | 2014 |
Silencing of COX-2 by RNAi modulates epithelial-mesenchymal transition in breast cancer cells partially dependent on the PGE2 cascade.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cadherins; Celecoxib; Cell Adhesion; Cell Movement; | 2014 |
Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway.
Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Proliferation; Cells, Cultured; Cyclooxyge | 2015 |
Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; Drug Synergism; Estrogen Recept | 2015 |
COX-2 modulates mammary tumor progression in response to collagen density.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Collagen Type I; Collagen Type I, alpha 1 Ch | 2016 |
Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Topics: 4-Butyrolactone; Breast Neoplasms; Carcinogenesis; Caspase 9; Celecoxib; Cell Line, Tumor; Cyclooxyg | 2016 |
Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.
Topics: Animals; Antigen Presentation; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Cell Line, Tumor; | 2016 |
Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR.
Topics: Aniline Compounds; Brain Neoplasms; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Cy | 2016 |
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Breast | 2016 |
[Postoperative inconveniences after breast cancer surgery].
Topics: Acetaminophen; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasms; Celecoxib; Cyc | 2008 |
[Multimodal treatment of pain and nausea in breast cancer surgery].
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasm | 2008 |
Reduced expression of cyclooxygenase-2 in primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxyge | 2008 |
The combined effects of celecoxib and minocycline hydrochloride on inhibiting the osseous metastasis of breast cancer in nude mice.
Topics: Alkaline Phosphatase; Animals; Apoptosis; Body Weight; Bone Neoplasms; Breast Neoplasms; Celecoxib; | 2008 |
[The effects of Celebrex on mammary tumorigenesis and aging in HER2/neu transgenic mice].
Topics: Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Cyclooxygenase | 2009 |
Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2009 |
[Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway].
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; | 2009 |
Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Breast Neoplasms; Butadienes; Celecoxib; Cell Line, | 2009 |
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, B | 2010 |
Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2011 |
Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2011 |
Role of COX-2 in tumorospheres derived from a breast cancer cell line.
Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase | 2011 |
Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.
Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug R | 2010 |
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; | 2011 |
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; | 2010 |
Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cell | 2011 |
How a new stratified adaptive phase II design could improve targeting population.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; DNA Damage; Dru | 2011 |
Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms.
Topics: Animals; Apoptosis; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclin D1; Cyclin E; Cyclin-Depen | 2011 |
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Topics: Analysis of Variance; Animals; Blotting, Western; Breast Neoplasms; Carcinoma, Ductal; Celecoxib; Ce | 2011 |
[Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 I | 2011 |
Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2012 |
[Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Celecoxib; Cl | 2012 |
Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Topics: Aspirin; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Survival; Chemokine CXCL10; Chemokine C | 2012 |
Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Breast Neoplasms; Cel | 2012 |
Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Celecoxib; Cell Division; Cell Line, Tu | 2003 |
Celecoxib reduces skin damage after radiation: selective reduction of chemokine and receptor mRNA expression in irradiated skin but not in irradiated mammary tumor.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Chemokines; Cyclooxygenase 2; Cyclooxygenase | 2003 |
Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro.
Topics: Apoptosis; Breast Neoplasms; Caspases; Celecoxib; Cell Division; Cyclooxygenase Inhibitors; DNA; End | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; C | 2003 |
Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.
Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Clone Cells; Collagen; Cyclooxyge | 2004 |
Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Interactions; Drug Therapy, Combin | 2004 |
Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarci | 2004 |
Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Celecoxib; Cell Division; Cyclooxy | 2004 |
COX-2 inhibitors still eyed for cancer prevention.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Colonic Neoplasms; Cycl | 2005 |
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Cyclooxygena | 2005 |
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Surviva | 2005 |
Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
Topics: Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Dose-R | 2005 |
Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Topics: Adenoviridae; Breast Neoplasms; Celecoxib; Cell Division; Cell Line, Tumor; Cell Survival; Cyclooxyg | 2005 |
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
Topics: Administration, Oral; Animals; Breast Neoplasms; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Po | 2006 |
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2005 |
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2006 |
Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species.
Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Blotting, Western; Breast Neoplasms; Celecoxib; Ce | 2006 |
Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Topics: Androstenedione; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cel | 2006 |
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Body Fluids; Breast Neoplasms; Car | 2006 |
Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; ATP-Binding Cassette | 2007 |
A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
Topics: Animals; Blood Vessels; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygen | 2006 |
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion.
Topics: 1,2-Dimethylhydrazine; Adjuvants, Immunologic; Animals; Anticarcinogenic Agents; Arginase; Breast Ne | 2007 |
Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C | 2007 |
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Contrast Media; Cyc | 2007 |
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Topics: Adenovirus E1A Proteins; Apoptosis; Blotting, Western; Breast Neoplasms; Celecoxib; Cell Survival; C | 2007 |
Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Hum | 2008 |
Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.
Topics: Animals; Anticarcinogenic Agents; Breast; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; | 2008 |
Trial endpoints for drug approval in oncology: Chemoprevention.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Female; Humans; Intestinal Polyps; Investigati | 2001 |
Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Blottin | 2001 |
COX-2 and prostanoid receptors: good targets for chemoprevention.
Topics: Animals; Breast Neoplasms; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Colonic Neop | 2002 |